Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zyban Clear all

Conditions: Healthy
Interventions: Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Depression
Interventions: naltrexone SR 32 mg/ bupropion SR 360 mg daily; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Postpartum Smoking Relapse
Interventions: Bupropion Extended Release Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Wilson Disease
Interventions: ALXN1840, Bupropion Hydrochloride; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Major Depressive Disorder
Interventions: AXS-05, Bupropion; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 1 more

Conditions: Obesity
Interventions: Weight Management Program (WMP), Medication for chronic weight management (Rx); Other · Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Major Depression
Interventions: Bupropion XL, Escitalopram; Drug
Lead sponsor: Emory University; Other
Eligibility: 25 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Methamphetamine Use Disorder
Interventions: bupropion SR; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Omaha, Nebraska

Conditions: Bipolar Disorder
Interventions: lithium carbonate, Depakote-ER, risperidone, olanzapine, paroxetine, bupropion, lamotrigine, venlafaxine, tranylcypromine, mirtazapine; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Smoking, Nicotine Dependence
Interventions: Bupropion; Drug
Lead sponsor: Henry Kranzler; Other
Eligibility: 18 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Newark, Delaware • Philadelphia, Pennsylvania

Conditions: Epilepsy, Major Depressive Disorder (MDD)
Interventions: Extended-release bupropion (HCl); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 24
States / cities: Beverly Hills, California • Sherman Oaks, California • Temecula, California + 21 more

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
Interventions: AXS-05, Bupropion, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 77
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more

Conditions: Obesity
Interventions: Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 35 Years to 60 Years
Enrollment: 30 participants
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Tobacco Use
Interventions: Personalized Smoking Cessation Facilitation Meetings, Personalized Smoking Cessation Pharmacotherapy, Personalized Text Messaging Support, SmokefreeVET, VA Quitline, Education about pharmacotherapy; Behavioral · Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: bupropion, transdermal nicotine patch; Drug
Lead sponsor: North Suffolk Mental Health Association; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Smoking Cessation
Interventions: Nicotine patch, nicotine inhaler, bupropion, Nicotine patch; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Pathological Gambling
Interventions: Bupropion, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Obesity
Interventions: Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide, Naltrexone-Bupropion, Phentermine-Topiramate, Semaglutide (Wegovy®); Other · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Tobacco Dependence, Smoking
Interventions: Active bupropion + counseling, Active bupropion, No counseling, Placebo medication + counseling, Placebo medication, No counseling; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 463 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cardiovascular Disease, Insulin Resistance
Interventions: Smoking cessation; Behavioral
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 25 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Smoking, Myocardial Infarction, Unstable Angina, Cardiovascular Disease
Interventions: bupropion SR (sustained-release); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia, Diabetes Mellitus, Type 2, Obesity
Interventions: Naltrexone, Bupropion, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Study Participants
Interventions: midazolam, metformin, bupropion, fenfluramine HCl; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder, Treatment Resistant Depression
Interventions: AXS-05, Bupropion SR; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions

A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

Bupropion for the Prevention of Postpartum Smoking Relapse

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Assessing Symptomatic Clinical Episodes in Depression

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

Bupropion in the Treatment of Methamphetamine Dependence

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women

Lethargic Depression Study

Addressing Dementia Via Agitation-Centered Evaluation

Anti-obesity Pharmacotherapy and Inflammation

Tobacco Cessation Treatment Preferences Among Veteran Smokers

Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia

Combination Medications vs. Patch Alone for Medically-Ill Smokers

Bupropion in the Treatment of Pathological Gambling

Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

Bupropion SR Plus Counseling for Smoking Cessation

Insulin Resistance in Smokers Undergoing Smoking Cessation

Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease

Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients